Relatlimab plus Nivolumab Clinical Trials

1 actively recruiting trial across 1 location

Also known as: Opdualag

Filter by location:

Irvine, California1 trial

Neoadjuvant Nivolumab + Relatlimab (Opdualag) Versus Nivolumab for Resectable High-Risk Basal Cell Carcinoma

University of California, Irvine

Phase 2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.